Bambuterol 20mg tablets
Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bambuterol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bambuterol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
WHO defined daily dose (DDD)
20 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 13 studies.
2017–2026
Showing all 13 studies, sorted by most relevant.
Shymaa M. Abd Elhaleem, F. Elsebaei, S. Shalan, et al.
Journal of Fluorescence, 2023
- Terbutaline
- Metal Nanoparticles
- Silver
Silver nanoparticles (AgNPs) were found to significantly quench the fluorescence of bambuterol hydrochloride (BAM) and its active metabolite terbutaline sulfate (TER). The intrinsic fluorescence intensity of each of BAM (at 264/292 nm) and TER (at 276/306 nm) decreased by the gradual addition of AgNPs. Quenching of the steady state fluorescence of BAM and TER probably resulted from the energy transfer to the photo-excited state of AgNPs. The estimated Stern-Volmer quenching constant at several temperature settings proved that the quenching mechanism of the two drugs was dynamic quenching in case of BAM while it was static quenching in case of TER. The number of binding sites, binding constants, and corresponding thermodynamic parameters depending on the interaction system were estimated at 293, 313, and 333 °K and the results obtained were interpreted.
Abstract licence: CC BY
Jie Wu, Z. Tan, M. Pistolozzi, et al.
Molecules, 2023
- Alzheimer Disease
- Butyrylcholinesterase
- Rivastigmine
Selective butyrylcholinesterase inhibitors are considered promising drug candidates for the treatment of Alzheimer’s disease. In this work, one rivastigmine–bambuterol hybrid (MTR-1) and fourteen of its analogues were synthesized, purified, and characterized. In vitro cholinesterase assays showed that all the compounds were more potent inhibitors of BChE when compared to AChE. Further investigations indicated that MTR-3 (IC50(AChE) > 100,000 nM, IC50(BChE) = 78 nM) was the best compound in the series, showing high butyrylcholinesterase selectivity and inhibition potency, the potential to permeate the blood–brain barrier, and longer-lasting BChE inhibition than bambuterol. These compounds could be used to discover novel specific BChE inhibitors for the treatment of Alzheimer’s disease.
Abstract licence: CC BY
Groo AC, Curel T, Malzert-Fréon A, et al.
2025
- Administration, Intranasal
- Alzheimer Disease
- Disease Models, Animal
Bambuterol is a long-acting anti-asthmatic prodrug which releases terbutaline. Terbutaline is an agonist of the β2-adrenergic receptors which is formed by decarbamoylation of bambuterol by butyrylcholinesterase. Inhibition of the latter, as well as activation of β2-AR, are of interest for the treatment of Alzheimer’s disease (AD). Combining these two activities, bambuterol could express a good clinical efficacy against AD. The present work firstly confirmed the capacity of bambuterol to display in cellulo neuroprotective activities, reduction of Tau hyperphosphorylation and preservation of synapses in rat hippocampal neuronal cultures intoxicated with Aβ peptides. Further, bambuterol, in the form of a liposomal gel, showed a good bioavailability in CNS after intranasal administration, which should reduce any side effects linked to peripheral terbutaline release. Indeed, even if the latter is more selective than other β2-mimetics towards bronchial β2-AR, cardiovascular effects (tachycardia, arrhythmias…) could occur upon cardiac β1-AR activation. Finally, intranasal administration of low doses of bambuterol gel in mice intoxicated with Aβ peptides, prevented long-term spatial memory impairment and showed beneficial effects on the survival of neurons and on synapse preservation. A mouse model suggests that an anti-asthmatic drug, bambuterol, could be repurposed against Alzheimer’s disease by administration through an intranasal route.
Abstract licence: CC BY-NC-ND
Lee HY, Shin J, Kim SH, et al.
2023
- COVID-19
- Capillary Leak Syndrome
- Hypoalbuminemia
BACKGROUND: Idiopathic systemic capillary leak syndrome (ISCLS) is a rare disease characterized by recurrent episodes of acute life-threatening attacks of shock, hemoconcentration, and hypoalbuminemia. Increase in capillary permeability results in reversible plasma movement into the interstitial spaces followed by appearance of related symptoms or complications, including renal failure. This condition can be potentially life-threatening; however, it is easily misdiagnosed. CASE PRESENTATION: A 47-year-old man with no previous medical history presented to the emergency department after experiencing general weakness and abdominal pain. He developed hypovolemic shock within 3 h of presentation and initial laboratory tests showed hemoconcentration, hypoalbuminemia and acute kidney injury. Following vigorous fluid therapy and supportive care, the patient recovered, but a similar episode recurred after 4 months without any specific trigger. Based on the combined clinical manifestations and laboratory findings of both the attacks, he was diagnosed with ISCLS. Symptomatic relief was achieved via oxygen supplementation and massive volume replacement using normal saline and the patient was prescribed bambuterol 10 mg and theophylline 400 mg once-a-day. He was discharged from the hospital on day 5 of hospitalization. Thereafter, the patient has been followed for 5 years without any symptoms or recurrence of ISCLS even in the situation of COVID-19 infection. CONCLUSIONS: ISCLS is an extremely infrequent and commonly misdiagnosed disease. However, early diagnosis, treatment and prophylaxis through accumulated clinical data can prevent ISCLS recurrence and the development of related fatal complications. Therefore, clinicians need to be well aware of the variety of clinical characteristics and treatment options of this disease.
Abstract licence: CC BY
Liangjun Deng, Le Tian, Dan Su, et al.
European journal of pharmacology, 2025
- Gastrointestinal Microbiome
- Anti-Inflammatory Agents
- Colitis
Asmaa El-Sayed, M. A. Sabry, H. Elmansi, et al.
BMC Chemistry, 2024
Abstract Quantitative 1 H-NMR became an increasingly important issue in pharmaceutical analytical chemistry. This study used NMR spectroscopy to assay the bronchodilator drug terbutaline sulfate and its pro-drug bambuterol hydrochloride in pure form and pharmaceutical preparations. The technique proceeded using deuterium oxide (D 2 O) as an 1 H-NMR solvent and phloroglucinol anhydrous as an internal standard (IS). Comparatively, to the phloroglucinol signal at 5.9 ppm, the resulting quantitative signals of the studied drugs were corrected. The terbutaline singlet signal at 6.3 ppm was chosen for quantification, while the bambuterol quantitative singlet signal was at 2.9 ppm. The two drugs were rectilinear over the concentration range of 1.0–16.0 mg/mL. LOD values were 0.19 and 0.21 mg/mL while LOQ values were 0.58 and 0.64 mg/mL for terbutaline and bambuterol respectively. The developed method has been validated according to the International Conference of Harmonization (ICH) regarding linearity, accuracy, precision, specificity, and robustness. A greenness profile assessment was applied, and the method proved to be green. The method enables the assay of the two drugs in pure drug and pharmaceutical preparations. The method also enables the assay of the two drugs in the presence of each other; thus, it is considered a stability-indicating method where terbutaline is an acid degradation product of bambuterol.
Abstract licence: CC BY
Manal Ibrahim, Nesrin K. Ramadan, Magda M. Ibrahim, et al.
Scientific Reports, 2026
A simple, eco-friendly, and precise isocratic RP-HPLC method was developed and validated for the simultaneous determination of bambuterol hydrochloride (BBL) and montelukast sodium (MTK). Separation was performed on an Inertsil C18 column (250 × 4.6 mm, 5 μm) using ethanol/0.025 M phosphate buffer (pH 3.0) at 70:30 (v/v) on an Agilent 1200 Infinity II system. The method complied with ICH criteria and showed linearity over 1.20–100.00 µg mL⁻¹ (BBL) and 5.00–100.00 µg mL⁻¹ (MTK). Application to a combined tablet dosage form yielded mean recoveries of 100.92 ± 1.08% (BBL) and 99.39 ± 1.41% (MTK). Dissolution profiling was performed in 900 mL of 0.5% sodium lauryl sulfate medium. Method greenness and sustainability were benchmarked against a reported procedure using multiple tools, Analytical Eco-Scale, MoGAPI, AGREE, RGB-12, D-CHEMS-1, GEAR, CaFRI, CACI, and BAGI demonstrating a safer solvent profile via ethanol/buffer. Notably, the separation time is longer (≈ 16 min), indicating a deliberate trade-off between reduced solvent hazard and throughput; analytical performance was maintained. Overall, the method offers a robust, greener alternative for routine assay and dissolution testing of BBL and MTK in pharmaceuticals.
Abstract licence: CC BY
Deng L, Tian L, Su D, et al.
2026
- Gastrointestinal Microbiome
- Colitis
- Intestinal Barrier Function
Silveșan L, Cimpoiu C, Casoni D
2026
- Antioxidants
- Adrenergic Agents
- Biphenyl Compounds
• New developed HPTLC-IA method for rapid screening of antioxidant potential of drugs • Different polarity stationary phases for predicting biological media interactions • Antioxidant potential profiling via selective stationary phases and two-radical assay • Predictive insight into membrane affinity/antioxidant potential of adrenergic drugs This study proposes a new approach for the in-vitro evaluation of antioxidant profile of adrenergic drugs using high-performance thin-layer chromatography coupled with image analysis techniques (HPTLC-IA). In this regard, stationary phases of different polarity (Silica gel and RP-8, RP-18W, CN and DIOL) were selected to simulate different environments and interactions that adrenergic drugs might encounter in the human body. Antioxidant activity was quantified using both DPPH • and ABTS ⁺• radical scavenging assays on all five stationary phases. Image processing and analysis was used to quantitatively compare the free radical scavenging potential of the analyzed compounds after converting the RGB image into different color channels, namely the green channel for the DPPH test, and the red channel for ABTS. Chromatographic data were processed using multivariate analysis. Results revealed that highly polar compounds, that is norepinephrine, etilefrine, metaraminol and midodrine exhibited strong interactions with silica gel but limited retention on reversed-phase, while lipophilic derivatives, namely naphazoline, xylometazoline, clenbuterol and bambuterol demonstrated strong affinity for non-polar and moderately polar phases, predicting good membrane penetration and blood-brain barrier permeability. Interestingly, some β-agonists (bambuterol, fenoterol, buphenine and irsoxsuprine) with polar groups showed unexpectedly weak silica gel retention, highlighting their dominant lipophilic contributions. Regarding the antioxidant activity, the results showed that phase interactions with the stationary phase significantly influenced the activity of adrenergic drugs. Thus, the polar phases (silica gel, DIOL) enhanced radical scavenging activity, whereas non-polar phases often reduced it. The developed HPTLC-IA method, integrating selective stationary phases and two-radical assays, offers a novel and cost-effective approach for screening the possible variation of antioxidant activity of drugs after their interaction with physiological media constituents.
Abstract licence: CC BY-NC-ND
Ibrahim M, Ramadan NK, Ibrahim MM, et al.
2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
13 hours
Mechanism
The pharmacologic effects of bambuterol are at least in part attributable to sti…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
20%
Half-life
13 hours
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 900 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC R03CC12
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bambuterol
Additional database identifiers
ChemSpider
49466
BindingDB
50235800
HUGO Gene Nomenclature Committee (HGNC)
HGNC:286
GenAtlas
ADRB2
GeneCards
ADRB2
GenBank Gene Database
Y00106
GenBank Protein Database
29371
Guide to Pharmacology
29
UniProt Accession
ADRB2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q3633651), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.